Skip to main content
. 2000 Mar;68(3):1574–1586. doi: 10.1128/iai.68.3.1574-1586.2000

TABLE 2.

ORFs encoded on B. burgdorferi 297 cp18-2

ORFa Alternate name Family bp
Orientationb Potential RBSc No. of amino acids Mol wt pI PSORT results
TMpred results
Borrelia paralogous family distribution
5′ 3′ Leader Leader Location No. of transmembrane domains Position Score DNA typed Paralog locatione
1  154 161 415 255 F 5′ truncated 85 9,880 3.98 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
2  155 415 648 234 F AACGAA-11 78 9,343 6.59 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
3  156 659 1945 1,287 F TGAGG-5 429 47,854 9.5 N Ce 1 134–153 919f C L, M, N, O, P, Q, R, S
4  157 2188 2649 462 F None 154 17,557 8.93 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
5  159 2656 3603 948 F AAAGGA-6 316 36,059 7.96 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
6  160 3624 4175 552 F AAAGGG-14 184 20,764 6.23 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
7  2.9 orf5 139 4208 4537 330 F None 110 12,848 5.68 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
8  2.9 orf6 140 4537 5412 876 F ATGGAGTT-6 292 33,272 5.02 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
9  2.9 orf7 141 5421 6023 602 F ATGGATAG-9 201 22,731 9.83 N Ce 1 50–67 684f C/L A, L, M, N, O, P, Q, R, S
10 2.9 orf8 142 6036 6845 809 F AGGGGGG-4 270 30614 5.64 N C 0 NA NA C/L A, L, M, N, O, P, Q, R, S
11 blyA 109 6925 7125 201 F AAAGGATT-5 67 7,477 9.71 Y, uncleaved IM 1 18–36 2876 C L, M, N, O, P, Q, R, S
12 blyB 111 7132 7476 344 F AAAGAGA-7 115 13,200 5.59 N C 0 NA NA C L, M, N, O, P, Q, R, S
13 2.9 orfC 143 7469 7801 333 F AAGGAAAG-8 111 12,698 0.18 Y, uncleaved IM 0 NA NA C/L A, G, L, M, N, O, P, Q, R, S
14 2.9 orfD 143 7797 8145 349 F AAAGAGG-5 117 13,616 9.22 Y, cleavedf P/OMf 1 5–22 1702 C/L A, G, L, M, N, O, P, Q, R, S
15 bdrB 80 8255 8719 465 F ATAAGGGAA-5 155 17,853 4.94 N IM 1 132–154 2639 C/L F, G, H, L, M, N, O, P, Q, R, S
16 rep- NA 8712 8371 342 R AAGTGAGG-16 114 10.38 Y, cleavedg IM 3 3–23 629 NA
32–50 2037
72–90 1786
17 mlp9 113 8828 9460 633 F AAAGGAG-5 211 24,081 5.04 Y, uncleavedh IMh 1  3–19 1336 C L, M, N, O, P, Q, R, S
18 36kDa 161 10563 9547 1,016 R AACGGAGG-6 339 39,970 7.91 N C 0 NA NA C C, L, M, N, O, P, Q, R, S
19 orfA 57 10943 12040 1,098 F AACGGAGA-6 366 44,309 9.65 N C 0 NA NA C/L/X X, A, C, D, E, F, G, H, I, L, M, N, O, P, Q, R, S, T, U
20 orf2 50 12054 12617 563 F TATGAGG-8 188 22,580 9.66 N C 0 NA NA C/ A, B, C, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S
21 orfC/parA 49 12596 13348 753 F CAAGGA-11 251 29,091 8.8 N Ce 1 139–154 711e C/L A, B,C, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S
22 orf3 32 13393 13950 558 F TAAGGAG-5 186 22,011 9.51 N C 0 NA NA C/L/X X, A, B, C, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, U
23 bdrA 80 13963 14484 522 F TAAGAGGA-4 174 20,268 5.58 N IM 1 147–167 2324 C/L F, G, H, L, M, N, O, P, Q, R, S
24 orf8 165 15022 16050 1,029 F AACGGAGG-6 343 39,666 5.15 N C 0 NA NA C C, L, M, N, O, P, Q, R, S
25 orf7 165 16072 16350 278 F AATGGAG-9 (L) 93 10,848 9.51 N Ce 1 69–89 833e C C, L, M, N, O, P, Q, R, S
26 orf10 144 16405 16827 423 F AGGAGAGG-6 141 16,745 9.61 N Ce 1 52–75 999e C/L A, L, M, N, O, P, Q, R, S
27 orf6 96 17612 16839 774 R AAAGGAGAGG-5 258 30,270 9.9 N Ce 1 74–90 550e C/L C, H, L, M, N, O, P, Q, R, S
28 p21 162 18043 18597 555 F TATGGAGA-6 185 20,747 7.19 Y, cleaved Lipoprotein 1  9–26 1632 C L, N, P, R
29 elpB2 163 18628 19845 1,218 F AGGGGAGA-6 406 46,539 5.02 Y, uncleaved IMh 1  6–21 1262 C F, L, N, O, P, Q
30 114 19998 20387 390 F AAAAG-12 (L) 130 15,661 9.64 Y, uncleaved IM 1  1–20 803 C L, N, O, P, Q, R
31 115 20747 21169 423 F TTAGGAGA-6 141 16,214 9.22 N C 0 NA NA C L, M, N, O, P, Q, R, S
a

 Potential pseudogenes are indicated in boldface. 

b

 F, forward; R, reverse. 

c

 Number following each potential ribosome binding site (RBS) indicates the distance to the AUG start codon. ORFs with putative leucine start codons are indicated by (L). 

d

 Refers to the type of genetic element on which ORFs belonging to the designated paralogous family have been described in B31: C, circular plasmid; L, linear plasmid; X, chromosome (BBGD). 

e

 Discrepancy between the presence of a predicted transmembrane domain (TMpred) and cytoplasm localization (PSORT) most likely due to relatively low (<1,000) TMpred score. 

f

 Experimental studies demonstrated that the 2.9 OrfD leader peptide is not cleaved (39). 

g

 Atypical leader peptide. 

h

 Mlp leader peptide has been shown to be lipid modified in vitro (39). ElpB2 contains appropriate lipid modification signal sequences.